Fermer le menu


Member of Lyonbiopole


Averoa, "the smart drug incubator", is dedicated to developing and registering drugs in the field of kidney disease.

Our expertise lies in identifying innovative products with the potential to meet major medical needs and enabling them to reach a stage of development to maximise their therapeutic and commercial value.


Application market: Metabolic Disorders - Endocrinology, Rare disease

Type of activity: Medical device, Therapeutics, Pharma or Biotech

Technologies: Small Molecules

Created on dec. 22nd, 2021 - 5 employees



11 Avenue Paul Verlaine 38100 Grenoble



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.